

UNIVERSITY OF MARYLAND
SCHOOL OF MEDICINE
INSTITUTE OF INTERNATIONAL MEDICINE
BALTIMORE, MARYLAND 21201



DIVISION OF EPIDEMIOLOGY AND BIostatISTICS

June 9, 1969

RE: IND 4466

Dr. Edwin M. Ortiz
FDA Director
Division of Metabolic Endocrine Drug Surveillance
Office of Marketed Drugs
Bureau of Medicine
200 C Street, S.W.
Washington, D.C. 20204

Dear Doctor Ortiz:

We are sending you today a copy of the confidential progress report for the University Group Diabetes Program, submitted to and discussed by the investigators at our recent meeting in Williamsburg.

The investigators have decided to discontinue the tolbutamide treatment and place these patients on placebo for continued observation under the protocol of the UGDP.

It has also been decided to publish our findings as soon as feasible. Your continued cooperation will be much appreciated.

With best regards.

Very sincerely yours,

A handwritten signature in cursive script, appearing to read "Christian R. Klimt".

Christian R. Klimt, M.D., Dr. P.H.
Professor and Director

CRK:bbb